topic

1237 Long term outcomes of severe endocrine immune-related adverse events (irAEs): adrenal insufficiency (AI) and insulin-dependent diabetes (IDDM)
Ben Nguyen, Neil J Shah, Andrea Knezevic, Monica Girotra

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1365; DOI: 10.1136/jitc-2023-SITC2023.1237
1238 Risk evaluation of immune checkpoint inhibitor diabetes through islet autoantibodies & HLA types in a large, real-world cohort
Zoe Quandt, Samantha Liang, Anastasia Lucas, Marshall Thompson, Ashis Saha, Christian Hammer, Kevan Herold, Arabella Young, Christine Spencer, Mark Anderson

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1366; DOI: 10.1136/jitc-2023-SITC2023.1238
1239 Major adverse cardiovascular events (MACE) in patients with melanoma receiving immune checkpoint inhibitors
Juan I Ruiz, Bo Zhao, Nicolas Palaskas, Anita Deswal, Hui Zhao, Jennifer McQuade, Maria E Suarez-Almazor

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1367; DOI: 10.1136/jitc-2023-SITC2023.1239
1240 Safety profile of pembrolizumab monotherapy versus pembrolizumab with combined treatments: analysis of french pharmacovigilance database
Samy Babai, Axelle Histe, Laure Thomas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1368; DOI: 10.1136/jitc-2023-SITC2023.1240
1241 Clusters of multi-organ toxicities are associated with improved survival among immune checkpoint inhibitor recipients: a population-level study
Wenxin Chen, Guihong Wan, Katie Roster, Nga Nguyen, Ahmad Rajesh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Kerry Reynolds, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R Leboeuf, Shawn Kwatra, Yevgeniy R Semenov

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1369-A1371; DOI: 10.1136/jitc-2023-SITC2023.1241
1242 Mouse model of CAR-related ICANS development after treatment with human CD19 CAR-T cells
Rita El Khoury, Barbara Camisa, Laura Falcone, Elena Tiziano, Rossana Norata, Francesca Sanvito, Tamara Canu, Patrizia D’Adamo, Alice Bergamini, Chiara Bonini, Monica Casucci

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1372; DOI: 10.1136/jitc-2023-SITC2023.1242
1243 High throughput autoantibody screening identifies antigens associated with the development of multiple immune related adverse events in melanoma
Catherine C Fahey, Douglas B Johnson, Justin M Balko

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1373; DOI: 10.1136/jitc-2023-SITC2023.1243
1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors
Stephanie Gu, Elena Goleva, Andrea P Moy, Kwami Ketosugbo, Lukas Kraehenbuehl, Tara Maier, Trina Salvador, Neil J Shah, Ryan Weight, Veronica Rotemberg, Jeffrey A Kern, Donald Y Leung, Mario E Lacouture

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1374; DOI: 10.1136/jitc-2023-SITC2023.1244
1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors
Chester J Kao, Soren Charmsaz, Madalena Brancati, Stephanie L Alden, Howard L Li, Aanika Balaji, Kabeer Munjal, Hua-Ling Tsai, Ludmila Danilova, Alexei Hernandez, Nicole Gross, Erin M Coyne, Sarah M Shin, Jennifer Durham, Brian Christmas, Christopher Thoburn, Maximilian F Konig, Evan J Lipson, Jarushka Naidoo, Laura Cappelli, Yasser Ged, Marina Barretti, Julie Brahmer, Jean Hoffman-Censits, Tanguy Y Seiwert, Rachel Garonce-Hediger, Sanjay Bansal, Laura Tang, Elizabeth M Jaffee, G Scott Chandler, Rajat Mohindra, Won Jin Ho, Mark Yarchoan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1375-A1377; DOI: 10.1136/jitc-2023-SITC2023.1245
1246 Immune related adverse events to checkpoint inhibitors are associated with altered regulatory T cell phenotypes and resemble CTLA4-deficient patients
James Maiarana, Carissa Elonen, Katy Beckermann, Jeffrey Rathmell, Douglas B Johnson, Janet Markle

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1378; DOI: 10.1136/jitc-2023-SITC2023.1246

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages